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Background: Radiation proctitis after intensity-modulated radiation therapy (IMRT) differs from that seen after pelvic
irradiation in that this adverse event is a result of high-dose radiation to a very small area in the rectum. We
evaluated the results of treatment for hemorrhagic proctitis after IMRT for prostate cancer.
Methods: Between November 2004 and February 2010, 403 patients with prostate cancer were treated with IMRT
at 2 institutions. Among these patients, 64 patients who developed late rectal bleeding were evaluated. Forty
patients had received IMRT using a linear accelerator and 24 by tomotherapy. Their median age was 72 years. Each
patient was assessed clinically and/or endoscopically. Depending on the severity, steroid suppositories or enemas
were administered up to twice daily and Argon plasma coagulation (APC) was performed up to 3 times. Response
to treatment was evaluated using the Rectal Bleeding Score (RBS), which is the sum of Frequency Score (graded
from 1 to 3 by frequency of bleeding) and Amount Score (graded from 1 to 3 by amount of bleeding). Stoppage of
bleeding over 3 months was scored as RBS 1.
Results: The median follow-up period for treatment of rectal bleeding was 35 months (range, 12–69 months).
Grade of bleeding was 1 in 31 patients, 2 in 26, and 3 in 7. Nineteen of 45 patients (42%) observed without
treatment showed improvement and bleeding stopped in 17 (38%), although mean RBS did not change
significantly. Eighteen of 29 patients (62%) treated with steroid suppositories or enemas showed improvement
(mean RBS, from 4.1 ± 1.0 to 3.0 ± 1.8, p= 0.003) and bleeding stopped in 9 (31%). One patient treated with steroid
enema 0.5-2 times a day for 12 months developed septic shock and died of multiple organ failure. All 12 patients
treated with APC showed improvement (mean RBS, 4.7 ± 1.2 to 2.3 ± 1.4, p< 0.001) and bleeding stopped in 5
(42%).
Conclusions: After adequate periods of observation, steroid suppositories/enemas are expected to be effective.
However, short duration of administration with appropriate dosage should be appropriate. Even when patients have
no response to pharmacotherapy, APC is effective.
Keywords: IMRT, Radiation proctitis, Late toxicity* Correspondence: gmst124i@gmail.com
1Department of Radiology, Nagoya City University Graduate School of
Medical Sciences, Nagoya, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya
467-8601, Japan
Full list of author information is available at the end of the article
© 2012 Takemoto et al.;licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.





n= 64 n= 40 n= 24
Median age 72 69 74
(range) (53–84) (55–79) (53–84)
D'Amico's risk
classification
Low 14 6 8
Intermediate 16 9 7
High 34 25 9
Clinical T stage
T1 22 12 10
T2 25 15 10
T3 17 13 4
Gleason sum score
≤ 6 25 13 12
7 25 17 8
≥ 8 14 10 4
Initial PSA (ng/ml)
< 10 31 18 13
10-20 18 10 8
> 20 15 12 3
Use of ADT 48 32 16
Use of antithrombotics 16 8 8
Presence of DM 10 4 6
ADT, androgen deprivation therapy; DM, diabetes mellitus.
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Chronic rectal bleeding is one of the most common
complications of radiation therapy for prostate cancer.
The etiology of radiation proctitis is considered to be
chronic mucosal ischemia caused by tissue fibrosis and
obliterative endarteritis. This injured rectal wall can
bleed easily, occasionally leading to a chronic ischemic
state and causing episodes of severe rectal bleeding [1].
Several studies reported on the management of radiation
proctitis after conventional pelvic radiotherapy. Trad-
itional pharmacotherapy of hemorrhagic radiation proc-
titis includes anti-inflammatory agents, rectal steroids,
rectal sucralfate, short-chain fatty acid enemas, and for-
malin therapy. Surgery is associated with high rates of
morbidity in patients with previous radiation therapy
and is therefore usually avoided [2]. Other treatment
approaches have included hormonal therapy and hyper-
baric oxygen. Endoscopic coagulation with a variety of
devices, such as the yttrium-aluminum-garnet laser,
heater and bipolar probes, and argon laser, has been
reported to be effective for the control of bleeding. How-
ever, argon plasma coagulation (APC) is now established
as an effective treatment for moderate or severe radi-
ation proctitis, reducing rectal bleeding and iron or
blood transfusion requirements by cauterizing mucosal
telangiectasias [3]. In addition, few complications have
been reported with the use of APC, with a reported rate
of 2.5% compared with 5% to 15% for laser treatment
[4].
Intensity-modulated radiation therapy (IMRT) is now
commonly used in place of conventional irradiation in
the treatment of localized prostatic cancer, and appears
to have yielded higher local control rates than conven-
tional radiotherapy [5-7]. In IMRT, radiation dose to the
rectal wall is planned to be as low as possible, but radi-
ation proctitis is still the most commonly encountered
complication [8-11]. Radiation proctitis after IMRT
seems to differ from that seen after whole-pelvic irradi-
ation because this adverse event is a result of high-dose
radiation to a very small area in the rectum. To our
knowledge, treatment of late rectal complication after
IMRT has not been reported systematically. We have
used steroid suppository or enema for pharmacotherapy,
and APC as an endoscopic therapy. The purpose of this
study was to evaluate the results of these treatments for
hemorrhagic proctitis after IMRT for prostate cancer.
Methods
Patients
Between November 2004 and February 2010, 403 patients
with localized prostate cancer were treated with IMRT with
or without hormone therapy at 2 institutions, Nagoya City
University Hospital (NCUH) and Nagoya Daini Red Cross
Hospital (NDRCH). Among these patients, 64 patients(16%) who developed late rectal bleeding were evaluated; 40
patients received IMRT using a linear accelerator at NCUH
(linac group) and 24 patients by helical tomotherapy at
NDRCH (tomotherapy group). The patient and tumor char-
acteristics are shown in Table 1. Their median age was
72 years (range, 53–84); patients treated with tomotherapy
were slightly older (p=0.0036). D’Amico’s risk classification
[12] was low in 14 patients, intermediate in 16, and high in
34. The American Joint Committee on Cancer clinical
T stage was T1 in 22 patients, T2 in 25, and T3 in 17. There
were more high-risk patients and T3 patients in the linac
group than in the tomotherapy group. Forty-eight patients
received hormone therapy; basically, neoadjuvant hor-
mone therapy was performed in intermediate- and high-
risk patients (according to D'Amico's classification) for
6–9 months (median, 7 months) and adjuvant hormone
therapy was given to high-risk patients for 2–3 years
(median, 28 months). Eighteen patients received antithrom-
botics before, during, and after IMRT for cardiovascular or
cerebrovascular disease. The IMRT studies were performed
prospectively with informed consent from all patients, but
the present study evaluating rectal bleeding was a retro-
spective one.
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assessed clinically and/or endoscopically. Late rectal
bleeding appeared no earlier than 3 months after the
initiation of IMRT. The bleeding was graded using Com-
mon Toxicity Criteria for Adverse Events (CTCAE)
version 4.0 and the Rectal Bleeding Score (RBS). This
scoring system has been elaborated by ourselves for this
study and is proposed to evaluate the grade of bleeding
and efficacy of treatment. The RBS is the sum of Fre-
quency Score and Amount Score. The Frequency Score
was evaluated as follows: score 3, 3 or more episodes of
bleeding per week; score 2, 0.5-2 episodes per week; and
score 1, less than one episode in 2 weeks. The Amount
Score was evaluated as follows: score 3, severe (reddened
toilet bowl); score 2, moderate (blood on stool surface);
and score 1, mild (blood spot on paper). When bleeding
had stopped for over 3 months, RBS was recorded as 1.
RBS was evaluated at the onset of bleeding and at the
latest follow-up (> 12 months after bleeding onset).
Intensity-modulated radiotherapy
All patients were immobilized in a supine position with a
vacuum bag system for their whole body and CT scans were
performed at a slice thickness of 3.2 mm. The clinical target
volume (CTV) included the prostate and seminal vesicles
(SV). The CTV of the SV depended on the T stage of the
patient: 1/3 volume of the SV for T1; 1/2 of the SV for T2;
and the whole SV for T3. The CTV was expanded in three
dimensions with 6- to 8-mm margins to obtain the planning
target volume (PTV). The rectum was contoured from the
level 10 mm below the lower PTV edge or the anal verge (a
higher one was chosen) to the level 10 mm above the upper
PTV edge. In the linac group, IMRT was delivered with 18-
MV photons of 5 static ports at 45°, 98°, 180°, 262°, and
315° using dynamic multileaf collimators. Eclipse Version
6.5/7.5 (Varian Medical Systems, Palo Alto, CA, USA) was
used for dose calculations. In the tomotherapy group, IMRT
was performed with 6-MV photons and the treatment plan-
ning system was Pinnacle3 (Philips Medical Systems, Madi-
son, WI). The planned doses were 70 to 78 Gy (median,
76 Gy) delivered in 33 to 39 fractions (median, 37 fractions).
The daily dose has been increased step by step from 2.0 Gy
to 2.1 Gy, and more recently to 2.2 Gy. As dose-volume
constraints for the rectum, < 35% and< 18% of the rectal
volume were allowed to receive more than 51.3-51.5% and
76.9-77.3% (depending on the protocol), respectively, of the
prescription dose. The maximum dose to the rectum was
set at 100.0-100.4% of the prescription dose. The mean
rectum volume was 59.0 ± 21.5 cc (median, 54.7 cc;
range, 25.4-160.1 cc), the mean %V40Gy (% of rectum
volume receiving≥ 40 Gy) was 36.7 ± 7.1% (median,
35.0%; range, 25.8-60.8%), and the mean %V70Gy (% of
rectum volume receiving≥ 70 Gy) was 8.8 ± 5.4% (me-
dian, 8.1%; range, 1.3-30.4%).Treatment of rectal bleeding
Except for 19 patients with relatively severe bleeding, 45
patients were first observed without treatment for at least
3 months. A steroid suppository or a steroid enema was
administered as pharmacotherapy in 29 patients; 18
received steroid as an initial therapy and 11 with poor im-
provement after observation over 3 months were given ster-
oid treatment. One of the following suppositories was
prescribed to 23 patients: PosterisanW Forte Ointment
(Maruho Co., Ltd., Osaka, Japan; hydrocortisone 2.5 mg+
Escherichia coli), NeriproctW Suppository (Bayer Yakuhin,
Ltd., Osaka, Japan; diflucortolone valerate 0.2 mg+ lidocaine
40 mg), and RinderonW Suppository 1.0 mg (Shionogi &
Co., Ltd., Osaka, Japan; betamethasone 1.0 mg). These sup-
positories were assumed to have similar efficacies, and
choice of the suppositories was dependent upon the
availability of the drugs at pharmacies of the patient’s prefer-
ence. In the early stage of this study, SteronemaW Enema
3 mg (Nichi-Iko Pharmaceutical Co., Ltd., Toyama, Japan;
betamethasone sodium phosphate 3.95 mg as betametha-
sone 3 mg) was initially prescribed to 6 patients. In 1
patient, a steroid suppository was used at first but treatment
was later changed to an enema because of ineffectiveness.
Steroid enemas were more difficult to use for patients than
steroid suppositories, and 2 patients could not undergo the
enema successfully, so treatment was changed to a supposi-
tory immediately. Therefore, more recent patients were pre-
ferably treated with a steroid suppository. The frequency of
steroid administration was once or twice daily, depending
on the severity.
APC was used in 12 patients. It was used as an initial
treatment in 1 patient with relatively severe bleeding, in 3
with poor improvement after observation over 3 months,
and in 8 with poor response to the pharmacotherapy. The
equipment used was a colonoscope (Olympus CF type
H260, Tokyo, Japan), APC equipment with an APC probe
with a diameter of 2.3 mm, an argon delivery unit, and a
high-frequency unit (ERBE APC2, ERBE Elektromedizin
GmbH, Tubingen, Germany). All patients were treated
without sedation. The forced mode was used at an argon
flow rate of 1.0 L/min with a power of 30–40 W. The fre-
quency of administration was up to 3 times, depending on
the severity.
Statistical analysis
Mann-Whitney’s U test was used to evaluate difference
in age between the linac and tomotherapy groups. Paired
t-tests were used to compare the changes after treat-
ments. The response rate over time of respective
strategies was calculated by the Kaplan-Meier method;
patients who showed no response and moved to the next
treatment were censored at that time. Log-rank tests
were used to examine the other clinical variables includ-
ing radiotherapy technique (linac vs. tomotherapy), use
Figure 1 (a, b, c): Changes in Rectal Bleeding Score (RBS) in the observation (a), steroid (b), and APC groups (c). Solid spots and error
bars represent the mean and standard deviation of the data.
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presence of diabetes mellitus (DM), rectal %V40Gy (≥ or
<median), and rectal %V70Gy (≥ or<median). Statis-
tical analyses were performed using the statistical soft-
ware StatView Version 5 (SAS Institute Inc., Cary, NC).
A p< 0.05 significance level (2-sided) was applied for all
statistical tests.
Results
The median follow-up period was 35 months (range, 12–
69 months). CTCAE grade of rectal bleeding was 1 in 31
patients (48%), 2 in 26 (41%), and 3 in 7 (11%). Rectal bleed-
ing occurred at 3–41 months (median, 13 months) after the
initiation of IMRT. Forty-five patients were observed with-
out treatment for at least 3 months, including patients who
were administered steroid or APC after the observation
period. Nineteen patients (42%) showed improvement and
4 showed exacerbations. The mean RBS changed from
3.1 ± 1.2 to 2.7 ± 1.6 (p = 0.25) and bleeding stopped in
17 patients (38%) (Figure 1a). The response rate was
29% at 6 months and 46% at 1 and 2 years (Figure 2).Figure 2 Kaplan-Meier curve for response in the observation
group (n = 45).Fourteen patients (31%) are still being observed with
a small amount of bleeding.
Twenty-nine patients received steroid suppositories
and/or enemas; 18 (62%) showed improvement and 3
showed exacerbations. The mean RBS improved signifi-
cantly from 4.1 + 1.0 to 3.0 + 1.8 (p = 0.003) and bleeding
stopped in 9 patients (31%) (Figure 1b). The response
rate was 41% at 6 months, 60% at 1 year, and 71% at
2 years (Figure 3). There was no significant difference in
response rate between steroid suppository and steroid
enema groups. All but one patient had no complication
with steroid therapy; one patient developed septic shock
and died of multiple organ failure after treatment with
steroid enema 0.5-2 times a day for 12 months. Long-
term rectal bleeding and/or prolonged use of steroid was
considered to be a possible cause of death.
All of 12 patients treated with APC (Figure 1c) showed
improvement within 2 months (mean RBS, from 4.7 ± 1.2
to 2.3 ± 1.4, p< 0.001) and bleeding stopped in 5
patients (42%). However, 2 or 3 sessions of treatment
were needed to stop or relieve bleeding in 5 patientsFigure 3 Kaplan-Meier curve for response in the steroid group
(n =29).
Table 2 Log-rank test for factors associated with improvement after observation.
Factors Groups (number of patients) Response rate at 1 year (%) P value
Age ≥ 71 (25)/≤ 70 (20) 54/35 0.12
IMRT method Linac (30)/Tomotherapy (15) 20/100 0.009
Use of ADT Yes (35)/No (10) 44/17 0.56
Use of antithrombotics Yes (26)/No (14) 61/49 0.66
Presence of DM Yes (6)/No (38) 67/42 0.37
Rectal %V40Gy ≥ 35.0% (27)/< 35.0% (17) 50/35 0.80
Rectal %V70Gy ≥ 8.1% (25)/< 8.1% (19) 33/65 0.005
ADT, androgen deprivation therapy; DM, diabetes mellitus. Rectal %V40/%70 Gy, % of rectum volume receiving≥ 40 or 70 Gy.
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treatment.
Furthermore, we examined factors related to response
rates after observation (Table 2) and steroid therapy
(Table 3). Upon observation, the tomotherapy-group
patients and patients with a rectal %V70Gy below the me-
dian (8.1%) had a better response rate at 1 year (p=0.009
and 0.005, respectively). DM patients responded early to
steroid therapy (p=0.02). Other factors were not associated
with response after observation or steroid therapy.
Discussion
The development of adverse events related to radiation
therapy depends on the dose and volume of normal tis-
sues irradiated [13]. Generally, doses exceeding 50 Gy in-
crease the potential of radiation damage, and the
incidence could be as high as 30% when the radiation
dose exceeds 70 Gy [14]. In most patients who had an
endoscopic examination in the present study, a relatively
small region of proctitis was detected, which was thought
to represent adverse events of IMRT delivering a high
dose to a limited area of the rectum. In our recent ana-
lysis, however, the incidence of radiation proctitis was
correlated with %V40Gy of the rectum rather than %
V60Gy or %V70Gy (A. Hayashi et al., manuscript in
preparation).
Patients observed for certain periods without treat-
ment showed slight improvement of the bleeding score
but this improvement was not statistically significant.
Since bleeding stopped spontaneously in 38% of the
patients, we think that patients with late rectal bleedingTable 3 Log-rank test for factors associated with the response
Factors Groups (number of patients)
Age ≥ 71 (17)/≤ 70 (12)
IMRT method Linac (16)/Tomotherapy (13)
Use of ADT Yes (21)/No (8)
Use of antithrombotics Yes (9)/No (15)
Presence of DM Yes (7)/No (22)
Rectal %V40Gy ≥ 35.0% (14)/< 35.0 % (15)
Rectal %V70Gy ≥ 8.1 % (15)/< 8.1 % (14)
ADT, androgen deprivation therapy; DM, diabetes mellitus; Rectal %V40/%70 Gy, %should be observed for 3 to 6 months unless their symp-
toms are severe or become exacerbated during the
follow-up period. In other studies too, most of the
patients showed improvement of endoscopic changes
after prostate radiotherapy without treatment [15,16].
Obviously, when patients show severe bleeding leading
to decrease of the hemoglobin level, immediate treat-
ment with steroids or APC is recommended. Patients
who had been treated by tomotherapy showed earlier re-
sponse, but this is thought to be due to a bias in patient
populations between the 2 institutes: the linac group had
more T3 patients (33%) than the tomotherapy group
(17%). The larger CTV for the SV due to the advanced
T stage might have caused worse adverse events in the
linac-group patients. The smaller rectal %V70Gy was
associated with a better response rate after observation,
while the %V40Gy was not. This result appears quite
reasonable, but does not agree with the above-
mentioned result that %V40Gy was correlated with the
incidence of rectal bleeding. We will further investigate
the issue with more patients and longer follow-up
periods.
Corticosteroids exert their anti-inflammatory effects in
part by inhibiting histamine release and thereby stabiliz-
ing mast cells. It is anticipated that corticosteroids will
help alleviate the symptoms of radiation proctitis. The
efficacy of steroid enemas in the management of chronic
radiation proctitis has yet to be proven, although slight
symptomatic alleviation was proven in patients treated
with steroid enemas and oral sulfasalazine in a small
prospective double-blind study [17,18]. Intestinalto steroid therapy.








of rectum volume receiving≥ 40 or 70 Gy.
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difficult to treat with steroid because radiation proctitis
or colitis is more widespread. We used not only steroid
enemas but also suppositories, in the expectation that
the suppositories could be effective for small regions of
proctitis after IMRT located just above the anal canal.
There have been some studies on pharmacotherapy of
rectal bleeding [19,20], but no report exists regarding
proctitis after IMRT, to the best of our knowledge. Over-
all, patients showed a significant improvement by steroid
suppository/enema therapy and bleeding stopped in 31%
in the present study. Therefore, steroid suppositories and
enemas seem to be worthy of consideration when bleed-
ing does not stop after observation. However, short dur-
ation of administration with appropriate dosage should
be appropriate because long-term, high-dose, frequent
administration of steroid suppositories/enemas could
cause several adverse effects including rounding of the
face (moon face), high blood pressure, exacerbation of
DM, and increased susceptibility to infection [21]. Rectal
steroids may show toxicity since their systemic bioavail-
ability is up to 44% of that of an equivalent oral dose
[22]. Earlier response was observed in patients with DM.
We have no explanation for this observation and it might
be related to the small number and biased selection of
patients for the Kaplan-Meier method. In one study,
patients treated with antithrombotics more often devel-
oped grade 2 or 3 late rectal toxicity after external beam
radiotherapy [23], but responses to treatments were not
investigated. We could not find any differences in the re-
sponse rates with or without antithrombotics.
APC uses the ‘plasma’ of ionized argon gas, which heats
the mucosal surface to a depth of 0.5 to 3 mm, coagulating
the superficial blood vessels [24]. Several studies reported
that APC successfully ameliorated rectal bleeding associated
with hemorrhagic radiation proctitis in 76-100% of cases
[3,25,26]. Each study used a different argon flow rate and
voltage, and complications also differed, including severe
ones such as rectal strictures and perforations. Although
there are no clear guidelines of precise APC settings for ra-
diation proctitis, it was reported that the argon rate should
be set at 1.0-1.5 L/min and a power of 40–50 W should be
used [24]. The power can be increased to 60 W for areas of
significant hemorrhage. Treatment is concentrated on the
area of most prominent telangiectasia, leaving areas of un-
treated mucosa in between. Single or repeat pulses of less
than 1 second are used, but care should be taken not to
overlap or treat a particular area of rectal mucosa repeat-
edly; otherwise this increases the risk for mucosal ulceration
that is characteristically slow to heal. Chino et al. [27]
also reported that low-power (40 W) and short-time
(1–2 sec) settings provided sufficient effect with low risk.
However, some patients who have severe proctitis, such
as dilated veins associated with ulcers and erosions,showed serious complications. In these cases, APC is un-
likely to be successful although it may ameliorate symp-
toms to some extent. We think that APC is effective
especially in proctitis following IMRT since almost all of
our patients had proctitis in so small areas of the rectum
that complications could be reduced. In our study, bleed-
ing stopped in 42% and no patients showed serious com-
plications after APC.
Conclusions
To manage rectal bleeding that does not disappear after ad-
equate periods of observation, a steroid suppository or
enema is expected to be effective and easy to use for
patients. Even when patients have no response to pharma-
cotherapy, APC is effective and stops or decreases bleeding
in a relatively short period.
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